BidaskClub downgraded shares of Acceleron Pharma (NASDAQ:XLRN) from a buy rating to a hold rating in a research report released on Friday.

Several other analysts also recently weighed in on XLRN. ValuEngine downgraded Acceleron Pharma from a hold rating to a sell rating in a research note on Friday, October 6th. HC Wainwright started coverage on Acceleron Pharma in a research note on Thursday, October 12th. They set a buy rating and a $57.00 target price for the company. Royal Bank of Canada restated a hold rating on shares of Acceleron Pharma in a research note on Thursday, November 2nd. Credit Suisse Group set a $51.00 target price on Acceleron Pharma and gave the company a buy rating in a research note on Tuesday, November 14th. Finally, Oppenheimer restated a hold rating on shares of Acceleron Pharma in a research note on Tuesday, November 14th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of $44.81.

Shares of Acceleron Pharma (XLRN) opened at $40.81 on Friday. The firm has a market capitalization of $1,800.00, a PE ratio of -15.82 and a beta of 1.45. Acceleron Pharma has a 52 week low of $23.07 and a 52 week high of $46.93.

In related news, SVP Christopher Rovaldi sold 11,000 shares of Acceleron Pharma stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $45.00, for a total value of $495,000.00. Following the completion of the transaction, the senior vice president now directly owns 35,701 shares in the company, valued at $1,606,545. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kevin F. Mclaughlin sold 19,000 shares of Acceleron Pharma stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $42.89, for a total value of $814,910.00. Following the completion of the transaction, the chief financial officer now owns 45,300 shares of the company’s stock, valued at $1,942,917. The disclosure for this sale can be found here. Insiders sold 146,021 shares of company stock valued at $5,529,598 over the last quarter. Insiders own 3.90% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Quantbot Technologies LP grew its stake in Acceleron Pharma by 416.3% in the third quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,352 shares in the last quarter. Public Employees Retirement Association of Colorado acquired a new position in Acceleron Pharma in the fourth quarter worth about $138,000. Oppenheimer & Co. Inc. acquired a new position in Acceleron Pharma in the third quarter worth about $225,000. Trexquant Investment LP acquired a new position in Acceleron Pharma in the third quarter worth about $266,000. Finally, PNC Financial Services Group Inc. grew its stake in Acceleron Pharma by 57.8% in the second quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 3,100 shares in the last quarter. Institutional investors and hedge funds own 85.62% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Acceleron Pharma (XLRN) Cut to Hold at BidaskClub” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/02/05/acceleron-pharma-xlrn-cut-to-hold-at-bidaskclub.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.